MedTrace Logo

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

NCT07091695 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-11-12

No results posted yet for this study

Summary

The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the real-world use of neoadjuvant nivolumab+relatlimab or nivolumab+ipilimumab

Conditions

Interventions

BIOLOGICAL

Nivolumab + relatlimab

As prescribed by the treating clinician

BIOLOGICAL

Nivolumab + ipilimumab

As prescribed by the treating clinician

Sponsors & Collaborators

Principal Investigators

  • Bristol Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-11
Primary Completion
2025-11-06
Completion
2025-11-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07091695 on ClinicalTrials.gov